Acorda Therapeutics Inc (ACORQ)

Acorda Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	117.63	118.57	129.07	152.97	192.41
Revenue Growth (YoY)	-0.79%	-8.14%	-15.62%	-20.50%	-59.19%
Cost of Revenue	15.28	30.33	40.79	33.51	34.85
Gross Profit	102.35	88.23	88.28	119.45	157.56
Selling, General & Admin	89.7	106.26	124.4	152.58	192.85
Research & Development	5.15	5.8	10.42	23.01	60.08
Other Operating Expenses	282.09	18.21	30.76	92.79	303.2
Operating Expenses	376.94	130.27	165.58	268.38	556.13
Operating Income	-274.59	-42.04	-77.3	-148.92	-398.57
Interest Expense / Income	31.53	30.2	30.04	30.57	21.87
Other Expense / Income	-10.1	-36.99	1.74	-71.83	-146.19
Pretax Income	-296.02	-35.25	-109.07	-107.67	-274.25
Income Tax	-43.17	30.67	-5.12	-8.07	-1.28
Net Income	-252.85	-65.92	-103.95	-99.59	-272.97
Shares Outstanding (Basic)	1	1	1	0	0
Shares Outstanding (Diluted)	1	1	1	0	0
Shares Change	22.85%	90.38%	31.38%	1.98%	0.47%
EPS (Basic)	-203.57	-65.23	-195.80	-246.40	-688.60
EPS (Diluted)	-203.57	-65.23	-195.80	-246.40	-688.60
Free Cash Flow	-14.25	-21.06	-41.51	-65.4	-218.59
Free Cash Flow Per Share	-11.47	-20.83	-78.17	-161.79	-551.51
Gross Margin	87.01%	74.42%	68.40%	78.09%	81.89%
Operating Margin	-233.43%	-35.45%	-59.89%	-97.36%	-207.15%
Profit Margin	-214.95%	-55.59%	-80.54%	-65.11%	-141.87%
Free Cash Flow Margin	-12.11%	-17.76%	-32.16%	-42.75%	-113.61%
EBITDA	-232.89	27.76	-45.09	-35.8	-217.8
EBITDA Margin	-197.98%	23.41%	-34.93%	-23.40%	-113.20%
Depreciation & Amortization	31.6	32.81	33.95	41.3	34.57
EBIT	-264.49	-5.05	-79.04	-77.09	-252.38
EBIT Margin	-224.84%	-4.26%	-61.24%	-50.40%	-131.17%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).